AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES…
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9…
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and…
